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Abstract
Background: Heat shock proteins (Hsp) are ubiquitously synthesised in virtually all species and it is hypothesised
that they might have beneficial health effects. Recent studies have identified circulating Hsp as an important
mediator in inflammation - the effects of low-grade inflammation in the aging process are overwhelming. While
much is known about intracellular Hsp70, scant data exist on circulating Hsp70 in the aging context. Therefore, the
objectives of this study were to investigate the effect of age and disease on circulating Hsp70 and, in particular, to
evaluate the association between circulating Hsp70 and inflammatory parameters.
Results: Serum Hsp70, Interleukin (IL) -10, IL-6 and Tumor Necrosis Factor (TNF) alpha concentrations were
determined in 90 hospitalised geriatric patients (aged 83 ± 6 years) and in 200 community-dwelling control
subjects (100 elderly, aged 74 ± 5 years, and 100 young, aged 23 ± 3 years). In the community-dwelling elderly,
serum Hsp70 and IL-10 concentrations were significantly lower and IL-6 was significantly higher when compared to
healthy young control subjects. Elderly patients presenting inflammation (CRP serum levels ≥5 mg/L) showed
significantly (p = 0.007) higher Hsp70 values; and Hsp70 correlated positively (p < 0.001) with IL-6 and CRP, but not
with TNF-alpha or IL-10. A significant association was also noted between Hsp70 levels and the degree of
dependency and cognitive decline in geriatric patients.
Conclusions: The present data provide new evidence that serum concentration of Hsp70 decreases with age in a
normal population. Our study also shows that higher levels of Hsp70 are associated with inflammation and frailty
in elderly patients.
Background
Heat shock proteins (Hsp) are primarily expressed as
intracellular proteins that exhibit a range of fundamental
roles necessary for cell survival. Intracellular functions
of Hsp include both specific biological actions that are
linked to a particular Hsp and more general chaperone
activities that result in the stabilisation and protection
of newly synthesised proteins, targeting ultimately
damaged proteins for degradation and transportation of
proteins to their sites of activity [1]. Although research
has mainly focused on intracellular Hsp, it is now
obvious that Hsp [2] as well as Hsp receptors [3] are
expressed on the cell surface and that Hsp are circulat-
ing in the blood [4]. Hsp can be secreted by viable cells,
such as peripheral blood mononuclear cells which are
thought to contribute significantly to circulating Hsp70
[5,6]. Extracellular Hsp have been reported to exhibit
beneficial properties, such as enhancing the survival of
cultured cells [7], and mitigating autoimmune disorders
[8-10]. The prevention or arrest of inflammatory
damage by Hsp is thought to involve T cell reactivity,
resulting in the enhancement and/or mitigation of speci-
fic cytokine profiles [8,11,12].
From a biological point of view, aging is associated with
a decrease in the homeostatic mechanisms that promote
adaptive responses to challenges. Numerous studies have
attested to the increased vulnerability of the elderly to
inflammatory challenges and their diminished capacity to
respond to stress. Studies in vitro and in animal models
have demonstrated that the stress response and the capa-
city to produce Hsp decrease with aging [4,13-15]. How-
ever, we have previously drawn attention to the higher
basal levels of Hsp70 that are found in unstimulated
lymphocytes and monocytes of the elderly compared to
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indicate that the Hsp system is in a more activated state
in elderly people. Despite the well-described age-related
changes at the cellular level, scant information is avail-
able on the Hsp present in the circulation [4,17,18]. We
reported previously that inflammation in elderly patients
resulted in higher circulating Hsp70 levels [17,19,20].
However, it remains unclear whether the concentrations
of circulating Hsp change as a person gets older, and
whether there is any relationship with the subclinical
inflammatory condition that accompanies normal aging.
Here we report on the serum levels of Hsp70 and the
relationship with pro- and anti-inflammatory cytokines
in a large number of normal young and elderly volun-
teers. Since aging results in an increased prevalence of
various diseases that might interfere with Hsp produc-
tion, we also investigated a group of geriatric patients.
Methods
Participants
We included 90 elderly patients (60 women and 30 men,
aged between 60 and 93 years, mean age 83.4 years (SD
5.6)), hospitalised consecutively in the geriatric unit at
the Universitair Ziekenhuis Brussel. For the evaluation
of the basic activities of daily living (bADL) a modified
scale was used, according to Katz et al. [21], to assess
the six bADL items (bathing, dressing, toileting, ambu-
lating or transferring, continence and feeding), on a
four-point scale ranging from completely independent
(1) to completely dependent (4). The Mini Mental State
Evaluation (MMSE) [22] was used to evaluate the cogni-
tive status of these patients, whenever the patient could
cooperate adequately. This tool, using a scoring system
between 0 and 30, covers five cognitive domains (orien-
tation, memory, attention, language and praxis) enabling
the rapid evaluation of cognitive functioning, with a
fairly high sensitivity, specificity and reproducibility.
Control groups comprised 100 physically independent
community-dwelling older subjects (51 women and
49 men, aged between 61 and 86 years, mean age
74.4 years (SD 4.6)), recruited from our research depart-
ment’s database of elderly volunteers and from senior
citizens’ organisations, and 100 young subjects (51
women and 49 men, aged between 20 and 30 years,
mean age 23 years (SD 2.9)), recruited from among the
staff and students of the Vrije Universiteit Brussel. We
excluded volunteers who had a chronic inflammatory
pathology or acute or uncontrolled conditions but, as
recommended by current guidelines [23], comorbidity
was not an exclusion criterion per se. Participants who
received anti-inflammatory medication other than low-
dose aspirin, used as a platelet antiaggregant, were
excluded.
The study was approved by the Vrije Universiteit
Brussel’s local ethical committee and all participants
gave their written informed consent.
Blood sampling
Hospitalised patients were assessed for participation in
the study within the first five days after admission. If
subjects participated in sports, measurements were per-
formed at least 12 hours after their last intensive physi-
cal activity. Venous blood samples were taken in the
morning from all participants; sera were separated from
blood cells and stored at -20°C.
Sandwich ELISA for Hsp70 determination in serum
Hsp70 in serum was detected using a commercial ELISA
kit (StressGen, Canada), as previously described, with
minor modifications [24]. All reagents, dilutions and cal-
culations were applied according to the manufacturer’s
instructions. The standard curve ranged from 0.20 ng/
mL to 12.5 ng/mL with a sensitivity of 90 pg/mL.
Other determinations
Sera were assayed for IL-6, TNF-alpha, IL-10 and CRP
using commercial ELISA kits (Invitrogen, Merelbeke,
Belgium). Intra-assay precision expressed as a coefficient
of variance (CV), as determined by the manufacturer for
low (L), normal (N) and high (H) standards, were:
for IL-6: CV-L = 7.7%, CV-N = 5.7%, CV-H = 5.1%; for
TNF-a: CV-L = 5.2%, CV-N = 4.1%, CV-H = 3.9%, and
for IL-10: CV-L = 2.9%, CV-N = 2.9%, CV-H = 4.8%.
For CRP, the CV-L was 1.3% and CV-H 2.1%. Serum
samples with a concentration of IL-6 lower than 7.8 pg/
mL, which was the lower detection limit for the stan-
dard kit, were re-analysed using the high-sensitivity IL-6
kit (Invitrogen, Merelbeke, Belgium) with a detection
l i m i to f0 . 1 6p g / m L ,a n dC V - L=8 . 3 % ,C V - N=6 . 2 % ,
CV-H = 4.7%. The detection limit for TNF-alpha and
IL-10 and CRP were 1.7 pg/mL and <1 pg/mL, and 0.2
mg/L respectively (as reported by the manufacturer). All
reagents were applied according to the manufacturer’s
instructions.
Data processing and statistical analysis
All analyses were performed using PASW Statistics
17.0.2 software (SPSS Inc, Illinois, USA). The differences
between the groups were assessed using one-way analy-
sis of variance (with Bonferroni post hoc testing). For
data that were not distributed normally, the non-
parametric Kruskall Wallis and the Mann-Whitney tests
were applied. Correlations between continuous para-
meters were evaluated using the Spearman test. To
allow for statistical analysis, values below the detection
limit for Hsp70, IL-6 and IL-10 were substituted by one
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ng/mL for Hsp70, 0.15 pg/mL for high sensitivity IL-6,
and 0.99 pg/mL for IL-10). In order to bring together
the results for IL-6 obtained via the standard and high-
sensitivity assays a method of ranking was applied
whereby the values obtained with the high-sensitivity kit
were ranked from low to high followed by the values
obtained with the standard kit from low to high. Differ-
ences between the groups in the proportion of subjects
with detectable or undetectable serum levels of Hsp70
and cytokines were analysed using Chi-square.
A p-value (2 sided) <0.05 was considered as statistically
significant.
Results
The characteristics of the three study groups at enrol-
ment are given in table 1. The main diagnosis justifying
the hospitalisation of the geriatric patients is given in
table 2. As expected, the elderly patients and the com-
munity-dwelling elderly had significantly higher comor-
bidity and medication intake than the young adults. The
mean age was significantly higher in the patient group
compared with the community-dwelling elderly group.
On the other hand, the body mass index was signifi-
cantly higher in the community-dwelling elderly than in
t h ey o u n ga d u l tg r o u p .O n l yt h ee l d e r l yp a t i e n tg r o u p
showed functional (an increased bADL score) and men-
tal decline (a low MMSE score).
Since there was no significant gender difference
observed in the levels of Hsp70, IL-6, IL-10, TNF-alpha
and CRP, the results from both sexes were pooled. As
shown in table 3, the median serum levels of Hsp70
were significantly different for geriatric patients, the
community-dwelling elderly and young adults (p <
0.001). This difference was mainly due to the signifi-
cantly higher number of older participants (more pro-
nounced for the non-inflammatory patients than for the
community-dwelling elderly people) for whom the
Hsp70 serum values were below the detection limit (p <
0.001). In fact, when participants with undetectable
Hsp70 serum levels - as well as the few outliers were
not taken into consideration - the values in the three
groups were not significantly different (Kruskall Wallis:
p = 0.114; see figure 1). Both IL-6 and TNF-alpha
serum levels were significantly higher in the commu-
nity-dwelling elderly compared to the young controls.
These cytokines were also significantly higher in the
patients compared to the controls. Conversely,
the serum levels of IL-10 were significantly lower in the
elderly participants compared to the young controls (see
table 3).
We found that in the control subjects age was related
negatively with Hsp70 and IL-10, and positively with IL-
6 and TNF-alpha serum levels (see table 4). In the
elderly patients, a positive association was observed
between the Hsp70 serum levels and those of IL-6 (r =
0.287; p < 0.05) and of CRP (r = 0.38; p < 0.001).
Among these patients, those without detectable Hsp70
levels gave lower values for IL-6 (p = 0.008) and CRP
(respectively median [inter-quartile range] 9.50 [4.11;
22.81] pg/mL and 5.59 [1.85; 23.6] mg/L) than those
with detectable levels (respectively 19.02 [8.95; 45.07]
pg/mL and 24.85 [5.00; 97.00] mg/L). No such relation-
ships were found for the elderly and young control
groups. Positive relationships were noted among the
cytokines, IL-6, TNF-alpha and IL-10, in both the
patient and control populations.
We found no significant differences in the levels of
serum Hsp70 among the various diagnoses for the elderly
patients (see table 2). However, since patients with infec-
tious disease tended to have higher Hsp70 values,
patients were further categorised according to their
inflammatory profile. When inflammation was present
(as assessed by CRP serum levels ≥5 mg/L), significantly
(p = 0.007) higher Hsp70 values were observed (see
table 3). Among the elderly patients there was a negative
Table 1 General characteristics of the participants
Parameter Geriatric patients Community-dwelling elderly Young adults
Male Female Male Female Male Female
N = 30 N = 60 N = 49 N = 51 N = 49 N = 51
Age (years) 83.4 ± 5.5* 83.3 ± 5.6* 74.7 ± 4.7
† 74.2 ± 4.5
† 23.4 ± 3.3 22.6 ± 2.5
Height (metres) 1.71 ± 0.08
† 1.59 ± 0.05
† 1.72 ± 0.05
† 1.60 ± 0.06
† 1.81 ± 0.08 1.69 ± 0.05
Weight (kg) 73.5 ± 11.7 62.2 ± 10.84
$ 78.7 ± 9.9 70.0 ± 12.1
† 76.7 ± 13.3 61.5 ± 7.7
BMI (kg/m
2) 25.1 ± 3.8 24.6 ± 4.1* 26.7 ± 3.2
† 27.2 ± 4.3
† 23.4 ± 3.8 21.7 ± 2.4
Medication (number) 9.4 ± 4.7* 8.2 ± 3.8* 2.6 ± 1.8
† 2.6 ± 1.8
† 0.3 ± 0.8 0.9 ± 0.9
Comorbidity (number) 7.0 ± 2.8* 6.4 ± 2.9* 1.4 ± 1.0
† 1.4 ± 1.1
† 0.1 ± 0.4 0.0 ± 0.1
bADL (score on 24) 12.1 ± 4.2* 13.2 ± 5.4* 6.0 ± 0.0 6.0 ± 0.0 6.0 ± 0.0 6.0 ± 0.0
MMSE (score on 30) 23.1 ± 5.2 n/a n/a n/a n/a
Values expressed as mean ± standard deviation, BMI = body mass index; bADL = basic activities of daily life; MMSE = mini-mental state examination; n/a = not
available, significantly different *from community-dwelling elderly and young adults,
†from young adults,
$from community-dwelling elderly (all One-way ANOVA
with Bonferroni post-hoc test p < 0.05).
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MMSE score and the Hsp70 serum values. As regards the
bADL score, a positive correlation (r = 0.25; p = 0.017;
N = 89) was found with the Hsp70 serum values.
Discussion
In this study, we provide new evidence regarding the
age-related differences in circulating Hsp70 levels by
comparing 190 elderly persons - stratified for clinical
profile - with 100 healthy young controls. Our results
show an age-related decrease in the serum levels of
Hsp70. The main difference was in the proportion of
participants for whom the Hsp serum levels were below
the detection limit, which was significantly higher in the
elderly controls and patients when compared to their
young counterparts (both p < 0.001). When only the
subjects with detectable Hsp70 levels were taken into
consideration and the few outlying high values were dis-
carded, there was no significant difference between the
levels of Hsp70 for the young controls compared to the
ambulatory elderly. Thus, contrary to our observations
for intracellular Hsp70 [16], it can be stated that circu-
lating Hsp70 decreases with aging in normal older sub-
jects. The results of a previous smaller-scale study [4]
concord with the age-related decrease in serum Hsp70
we report here. Other studies dealing with the effect of
age on circulating Hsp70 either failed to include subjects
over 50 years of age [25], or focused on exceptional
longevity in centenarians [26]. Although the mechan-
isms underlying the age-related effects on circulating
Hsp70 are largely unknown, evidence from in vitro stu-
dies suggest that age-related differences in the produc-
tion of intracellular Hsp70 might reflect the limited
transcription of the heat shock genes, which has been
confirmed as due to reduced activation and binding of
the HSF 1 to the HSE and/or an impairment in the
post-translational processing of Hsp70 mRNA, resulting
in its impaired nuclear transport [4].
In geriatric non-inflammatory patients, Hsp70 was less
detectable and circulating levels were lower than for the
Table 3 Hsp70 and cytokine serum concentrations
Parameter Infl. Geriatric Patients
N=5 6
Non-infl. Geriatric Patients
N=3 4
Community-Dwelling Elderly
N = 100
Young Adults
N = 100
Hsp70 (ng/mL)
Median [IQR]* 0.22 [0.19; 0.58] 0.19 [0.19; 0.21]
† 0.19 [0.19; 0.50]
‡ 0.40 [0.19; 0.67]
‡$
Detectable/Undetectable* 29/27 9/25
† 47/53
‡ 72/28
†‡$
IL-6 (pg/mL Standard)
Median [IQR]
a* 27.03 [16.38; 48.84] 12.78 [8.95; 16.88]
† 13.15 [9.99; 16.99]
† 9.29 [8.56; 11.97]
†$
Detectable/Undetectable* 46/10 13/21
† 28/72
† 19/81
†‡
IL-6 (pg/mL Hs)
Median [IQR]
a* 3.95 [2.69; 6.82] 4.32 [2.49; 4.91] 2.09 [1.29; 3.27]
†‡ 0.89 [0.70; 1.46]
†‡$
Detectable/Undetectable* 10/0 21/0 71/1 63/18
‡
TNF-alpha (pg/mL)
Median [IQR]* 15.65 [11.87; 21.66] 12.93 [10.06; 17.99]
† 12.49 [10.81; 15.73]
† 12.07 [10.09; 13.87]
†$
Detectable/Undetectable 56/0 34/0 100/0 100/0
IL-10 (pg/mL)
Median [IQR]* 0.99 [0.99; 2.12] 0.99 [0.99; 0.99]
† 0.99 [0.99; 1.81]
‡ 1.97 [0.99; 2.97]
†‡$
Detectable/Undetectable* 19/37 5/29
† 45/55
‡ 64/36
†‡$
IQR = interquartile range (percentile25; percentile 75); Infl = inflammatory (CRP serum concentration ≥5 mg/L);
aValues based on samples with detectable
concentrations only; Standard = standard IL-6 kit with a detection limit of 7.8 pg/mL; Hs = high-sensitivity IL-6 kit with a detection limit of 0.16 pg/mL.
*Significant differences among groups (Kruskall-Wallis test or Chi-Square test p < 0.001); significantly different from
†Inflammatory geriatric patients,
‡Non-inflammatory geriatric patients,
$ Community-dwelling elderly (Mann-Whitney U test or Chi-Square test p < 0.05).
Table 2 Main diagnosis and Hsp70 serum concentrations
among the elderly patients
Diagnosis Hsp70 Inflam/Non-inflam
Median [IQR] N
Infectious disease 0.42 [0.19; 0.76] 17/1
Cardiovascular disease 0.19 [0.19; 0.39] 11/5
Neuropsychological disorder 0.19 [0.19; 0.21] 4/7
Cancer 0.19 [0.19; 0.55] 6/4
Musculoskeletal disorder 0.21 [0.19; 1.54] 6/4
Gastrointestinal disorder 0.19 [0.19; 0.19] 5/4
Cerebrovascular disease 0.19 [0.19; 0.19] 2/2
Haematological disorder 0.19 [0.19; 0.88] 0/3
Respiratory disorder 0.35 [0.19; 1.81] 1/2
Rheumatological disorder 0.19 1/1
Diabetes mellitus 0.19 1/0
Frailty 0.24 1/0
Otorhinolaryngical disease 0.23 0/1
Urological disorder 0.19 1/0
IQR: interquartile range (percentile25; percentile75); no significant difference
in Hsp70 concentration between the various diagnostic groups (Kruskall Wallis
test p = 0.14; performed for those diagnostic groups with >4 participants);
Inflam = inflammatory (CRP serum concentration ≥5 mg/L).
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this was not the case for inflammatory geriatric patients
who had higher circulating Hsp70 values than the non-
inflammatory ones. A positive association was observed
between the Hsp70 serum levels and the levels of CRP
and IL-6 in patients, in agreement with previous obser-
vations we made about geriatric patients [19,20]. In vitro
studies [27,28] have shown that IL-6 can up-regulate the
production of Hsp through signal transduction by the
transcription factors Nuclear Factor IL-6 and the Signal
Transducer and Activator of Transcription (STAT)-3.
Similarly, other cytokines, including TNF-alpha [29,30]
and INF-gamma through STAT-1 signalling [31], have
been shown to stimulate the production of Hsp70.
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Figure 1 Hsp70 concentrations in the various categories of participants. Serum Hsp70 levels were significantly higher in the young
compared to the elderly subjects. However, when participants with undetectable Hsp70 serum levels - as well as the few outliers - were
excluded, the values in the three groups were not significantly different (Kruskall Wallis: p = 0.114).
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Page 5 of 8In the present study, neither TNF-alpha nor IL-10
serum levels indicated a relationship with circulating
Hsp70.
As expected, the serum levels of both TNF-alpha and
IL-6 increased significantly with age in the combined
control groups, while the IL-10 serum level decreased.
An age-related decrease in IL-10 was reported in mice
by Ye and Johnson [32]. Many other studies have also
described increased TNF-alpha and IL-6 concentrations
with age [15,33,34], which were associated with a spec-
trum of age-related conditions, including low-grade
inflammation, frailty and functional decline [35]. The
fact that IL-6 was related to Hsp70 only in the patients
and not in the control participants might be explained
by differences between patients and controls in the com-
plex cytokine environment.
In the present study, a significant difference was noted
in Hsp70 levels between elderly controls and non-
inflammatory elderly patients. It is difficult to draw any
parallels between the mechanisms leading to Hsp70 pro-
d u c t i o ni np a t i e n t sa n dt h o s ei n v o l v e di nt h em o r e
restrained changes associated with aging in normal indi-
viduals. In patients, and depending on the pathological
situation, differential associations between Hsp70 and
disease status have been reported. For instance, higher
circulating levels of Hsp70 have been shown in patients
with chronic heart failure [36] and coronary artery dis-
eases [37], which was suggested to be associated with
stretch and decreased myocyte shortening [38]. Conver-
sely, reduced Hsp70 levels were observed in patients
with chronic obstructive pulmonary disease [39] and in
AIDS patients [40]. More notably, in the present study
there was a broad case mix, which might have neutra-
lised specific associations between Hsp70 and a particu-
lar pathology.
It has been reported that in the absence of serious
inflammatory conditions, low levels of serum Hsp70 are
associated with successful biological aging [26] and might
reflect a strong anti-inflammatory status of an indivi-
dual’s immune system [41]. In the elderly patient group,
Hsp70 was associated positively with clinical markers of
frailty. Indeed, Hsp70 serum levels were significantly
higher in the most frail patients, as documented by the
positive correlation with the level of physical dependency
(bADL score: r = 0.24; p = 0.022) and the negative corre-
lation with cognitive functioning (MMSE score: r = -0.37;
p = 0.004). These results are in accordance with our pre-
vious report on elderly nursing-home residents, showing
higher circulating Hsp70 with increasing dependency
[42]. Also, in the study on elderly persons with excep-
tional longevity, mentioned above [26], it appeared that
higher circulating Hsp70 levels indicated a poorer clinical
condition. To our knowledge, relationships between
dementia and circulating Hsp70 have not been estab-
lished; only one report mentions increased plasma Hsp70
levels in patients with vascular mild cognitive impairment
[43]. The exact mechanisms behind such a relationship
remain uncertain, but might involve increased oxidative
stress [44-46]. Following these observations, it can be
hypothesised that Hsp70 in serum has beneficial effects
during acute elevations (of short duration), but is related
to negative clinical conditions when chronically elevated.
Table 4 Relationship between the inflammatory parameters and Hsp70 in patients and control subjects
Age (years) CRP (mg/L) TNF-alpha (pg/mL) IL-6 (Rank order)
a IL-10 (pg/mL)
Hsp70 (ng/mL)
Patients (n = 90) -0.106 0.379** 0.145 0.287** 0.045
Controls (n = 200) -0.194** NA -0.035 -0.118 -0.041
IL-10 (pg/mL)
Patients (n = 90) -0.051 0.223* 0.327** 0.234*
Controls (n = 200) -0.185** NA 0.162* 0.073
IL-6 (Rankorder)
a
Patients (n = 90) 0.117 0.699** 0.354**
Controls (n = 200) 0.421** NA 0.332**
TNF-alpha (pg/mL)
Patients (n = 90) 0.110 0.303**
Controls (n = 200) 0.149*N A
CRP (mg/L)
Patients (n = 90) -0.029
Controls (n = 200) NA
NA = not applicable;
aSerum samples with the concentration of IL-6 lower than 7.8 pg/mL, which was the lower detection limit for the standard IL-6 kit, were re-
analysed using the high-sensitive IL-6 kit with a detection limit of 0.16 pg/mL. In order to bring results for IL-6 obtained by the standard and high-sensitivity
assays together, a ranking method was applied whereby the values obtained with the high-sensitivity kit were ranked from low to high followed by the values
obtained with the standard kit from low to high. Values represent Spearman’s rho correlation coefficients, * p < 0.05, ** p < 0.001.
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In conclusion, the present study shows that the serum
concentration of Hsp70 decreases with age in a normal
population, adding further evidence to the concept that
the capacity to produce Hsp70 decreases with aging. In
addition, our study suggests that increased serum levels
of Hsp70 are associated with frail health, as documented
by worse bADL and MMSE scores in patients. Inflam-
matory pathology in elderly patients is accompanied by
higher Hsp70 levels. These results pave the way for a
more detailed exploration of Hsp70 in frailty. In particu-
lar, understanding whether Hsp70 plays a role in frailty
or is only a consequence of frailty, is intriguing.
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